



## ***In vivo* repopulation of cytoplasmically gene transferred hematopoietic cells by temperature-sensitive mutant of recombinant Sendai viral vector <sup>☆</sup>**

Kumi Yoshida <sup>a</sup>, Yoshikazu Yonemitsu <sup>a,\*</sup>, Sakura Tanaka <sup>a</sup>, Shuro Yoshida <sup>b</sup>,  
Satoko Shibata <sup>a</sup>, Haruhiko Kondo <sup>a</sup>, Shinji Okano <sup>a</sup>, Fumihiko Ishikawa <sup>b,c</sup>,  
Koichi Akashi <sup>d</sup>, Makoto Inoue <sup>e</sup>, Mamoru Hasegawa <sup>e</sup>, Katsuo Sueishi <sup>a</sup>

<sup>a</sup> Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

<sup>b</sup> Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

<sup>c</sup> RIKEN, Research Center for Allergy and Immunology, Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-Ku, Yokohama, Kanagawa 230-0045, Japan

<sup>d</sup> Center for Cellular and Molecular Medicine, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

<sup>e</sup> DNAVEC Corporation, 1-25-11 Kannondai, Tsukuba-shi, Ibaraki 305-0856, Japan

Received 19 July 2007

Available online 30 July 2007

### **Abstract**

Recent clinical studies revealed ‘proof of concept’ of gene therapy targeting hematopoietic stem cells (HSCs) to treat hematopoietic disorders. However, vector integration-related adverse events of retroviral vectors have slowed progress in this field. As an initial step to overcoming this hurdle, we examined the potential of an improved cytoplasmic RNA vector, temperature-sensitive mutant non-transmissible recombinant Sendai virus (ts-rSeV/dF), for gene transfer to murine HSCs and progenitors. Both conventional vector and ts-rSeV/dF-GFP showed efficient gene transfer to T-lymphocyte-depleted syngeneic bone marrow cells (BMCs) (>85%), but only BMCs treated with ts-rSeV/dF-GFP but not with conventional vector efficiently repopulated in the recipient mice, associated with multilineage differentiation *in vitro* and *in vivo*. To our knowledge, this is the first demonstration of the *in vivo* reconstruction of hematopoietic series by cytoplasmically gene transferred BMCs, that warrants further investigation to realize this strategy in clinical settings.

© 2007 Elsevier Inc. All rights reserved.

**Keywords:** Sendai viral vector; Hematopoietic stem cells; Cytoplasmic gene therapy; Severe immunodeficiency syndrome; Bone marrow transplantation

<sup>☆</sup> This work was supported in part by a Grant-in-Aid (to Y.Y. and K.S.) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology, and Research Grants from the Sankyo Foundation of Life Science (to Y.Y.), Mitsubishi Pharma Research Foundation (to Y.Y.), and the Uehara Memorial Foundation (to Y.Y.).

\* Corresponding author.

E-mail addresses: yonemitu@med.kyushu-u.ac.jp, yonemitu@faculty.chiba-u.jp (Y. Yonemitsu), sueishi@pathol1.med.kyushu-u.ac.jp (K. Sueishi).

<sup>1</sup> Present address: Department of Gene Therapy, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. Fax: +81 43 226 2973.

Gene therapy targeting hematopoietic cells is a promising strategy for treating inherited hematopoietic disorders. Hematopoietic stem cells (HSCs) in particular are an ideal target, because they can reconstitute the entire hematopoietic system in a recipient during a lifetime. Recent clinical success in clinical gene therapy for X-linked SCID using a retroviral vector expressing the common  $\gamma$ -chain revealed the ‘proof of concept’ of the strategy and has given encouragement to physicians, patients, and scientists, but a serious adverse event, T-cell leukemia, which is related to the insertion of a pro-viral genome into the host chromosome

mediated by retroviral vector, is an obstacle to developing the gene therapy strategies in this field [1–4].

We recently developed a novel viral vector for efficient gene transfer, recombinant Sendai virus (rSeV), and demonstrated highly efficient gene transfer to various organs *in vivo*, including airway epithelial cells, vascular tissue, skeletal muscle, and joint synovium [5–8] by using replication-competent additive-type rSeV; these findings are also consistent with a clinically available fusion gene-deleted non-transmissible rSeV (rSeV/dF) [9]. Since rSeVs uses a cytoplasmic transcription system, it can mediate gene transfer to a cytoplasmic location without the DNA phase [10] and therefore theoretically avoid a vector integration-related adverse event. In addition, there are technical advantages in the use of rSeVs for gene transfer to HSCs. First, vector particles can be easily concentrated to high titers, unlike retroviral vectors. Second, and most importantly, the modalities of target cell processing and viral transduction are technically non-demanding and feasible in clinical situations that require transduction into large numbers of target cells. Using replication-competent additive-type rSeV, we previously demonstrated a highly efficient gene transfer to HSCs derived from human cord blood preserving their functions to differentiate into the entire hematopoiesis series *in vitro* [11]; however, repopulation of HSCs has been unsuccessful when these cells were treated with additive-type rSeV as well as rSeV/dF (unpublished data). Therefore, we have again turned our focus to improving the rSeV system in view of reduced immunogenicity and cytotoxicity.

Recently, we newly developed temperature-sensitive mutant non-transmissible rSeV (rSeV/dFP<sup>ts</sup>M<sup>ts</sup>HN<sup>ts</sup>L<sup>ts</sup>, abbreviated as ts-rSeV/dF) [12,13], as an improved version of rSeV/dF. This new vector loses the expression of envelope-related genes M and HN at 37 °C [12,13], resulting in dramatically reduced cytotoxicity as well as innate immune responses in the murine lung [14].

In this study, therefore, we examined the potential of SeV as a cytoplasmic transcription system for gene transfer to HSCs and hematopoietic progenitors.

## Materials and methods

**Animals.** Female 7-week-old C57BL/6 mice of Charles River grade were obtained from KBT Orientals Co., Ltd. (Tosu, Saga, Japan) and kept under specific pathogen-free and humane conditions. The GFP-TG mice (C57BL/6-TgN(act-EGFP) OsbC14-Y01-FM131) [15] were a gift from Prof. Okabe, Osaka University, Osaka, Japan. These mice were used for all experiments except the CTL assay. All animal experiments were carried out according to the protocols approved by the Institutional Committee for Animal Experiments and by the Institutional Committee for Recombinant DNA and Infectious Pathogen Experiments, Kyushu University. The experiments were carried out in accordance with recommendations for the proper care and use of laboratory animals and according to The Law (No. 105) and Notification (No. 6) of the Japanese Government.

**rSeV vectors.** rSeV/dF-GFP and ts-rSeV/dF-GFP were constructed as previously described [9,12,13]. A series of F-deficient SeV vectors were prepared by using recombinant LLC-MK<sub>2</sub> cells carrying the F gene (LLC-MK<sub>2</sub>/F7). An adenovirus vector, AxCANCre, expressing Cre recombinase

was used for the induction of F protein in LLC-MK<sub>2</sub>/F7 cells (referred to as LLC-MK<sub>2</sub>/F7/A). Recombinant vaccinia virus vTF7-3 carrying T7 RNA polymerase was inactivated with psoralen and long-wave UV irradiation, and then used for the ribonucleoprotein complex recovery. The viral vectors were further amplified by several rounds of propagation. The titers of the recovered viral vectors were expressed as cell infectious units [9].

**Gene transfer to BM cells and BMT.** BMCs from donor mice were flushed under sterile conditions with RPMI 1640 with 10% fetal calf serum from the medullary cavities of tibiae and femurs using a 23-gauge needle. Red blood cells were depleted using Lysing buffer (0.38% NH<sub>4</sub>Cl, Tris-HCl, pH 7.65), and mature T-cells were depleted with anti-Thy1.2 monoclonal antibody (Sigma, St. Louis) plus selected rabbit complement (Cedalene, Ontario, Canada). Gene transfer was carried out by simply adding MOI = 10 of vector solution to the media at 37 °C for 1 h, and 2 × 10<sup>7</sup> (C57BL/6) BMCs were given by tail vein injection. For bone marrow ablation, the recipient mice were treated by whole-body  $\gamma$ -irradiation at lethal dose (10 Gy) 4–5 h before BMT. For blood cell count, PBCs were obtained via the tail vein, diluted, and counted by an automatic cytometer (Celltac $\alpha$ MEK-6158 NIHON KOHDEN, Tokyo, Japan).

**Flow cytometry analyses.** At appropriate time points, PBCs or tissue samples were obtained and subjected to flow cytometry analysis. For immune cell subset analysis, cells from each organ were stained with CD3-APC/DX5-PE (for pan-T-cells), CD3-APC/CD4-PE (CD4/T-cells), CD3-APC/CD8-PE (CD8/T-cells), CD11b-PE/CD11c-APC (monocyte/macrophages), and B220-APC/IgM-PE (B-cells) (all antibodies were from BD Pharmingen, CA) by FACSCalibur (Becton Dickinson, CA). For *in vitro* analysis of each progenitor population, whole BMCs, 48 h after ts-rSeV/dF-GFP exposure, were stained with biotin-conjugated anti-lineage (lineage panel; BD pharmingen), anti-Sca-1-APC, anti-c-kit-PE antibodies and streptavidin for 30 min. Propidium iodide-positive dead cells were excluded. Data were evaluated using Cellquest™ (Becton Dickinson) or Flowjo (Tree Star Inc., CA) software.

**Enrichment of HSCs and colony assay.** Enrichment of HSC via FACS Aria (Becton Dickinson) was previously described [16,17]. Briefly, mononuclear cells were obtained from BMCs supplemented with Lympholyte-M (Cedalene), and lineage<sup>+</sup> cells were removed with sheep anti-rat IgG conjugated magnetic beads (Dyna, A.S.), and with anti-c-kit-APC antibody and anti-APC microbeads (Dyna, A.S.). The remaining cells were stained with biotin-conjugated anti-lineage-cocktail (BD Pharmingen), streptavidin-perCP-Cy5, anti-c-Kit-APC, and anti-Sca-1-PE, and were sorted in duplicate. For the colony assays, an enriched HSC population was cultured in MethoCult™ Media (M3434; StemCell Technologies, Vancouver, BC, Canada), and exposed to ts-rSeV/dF-GFP for 1 h. After washing, 1000 cells were cultured in 1 ml Methocult media per dish (35 mm) for 10–12 days. CFU-Mix colonies were observed and analysed by BZ-8000 and BZ-Analyzer (KYENECE, Osaka, Japan).

**Statistical analysis.** All data are expressed as the mean  $\pm$  SD, and were analyzed by one-way ANOVA with Fisher's adjustment, with the exception of the data on animal survival. Survival was plotted using Kaplan–Meier curves, and statistical relevance was determined using a log–rank comparison.  $P < 0.05$  was considered significant.

## Results

### *Efficient engraftment and repopulation of cytoplasmically gene transferred murine bone marrow cells by ts-rSeV/dF in C57BL/6 syngeneic recipient mice*

We first evaluated the gene transfer efficiency of recombinant ts-rSeV/dF-GFP compared to that with rSeV/dF-GFP mediated gene transfer to murine (7-week-old female C57BL/6) BMCs depleted with erythrocyte and mature T-cells. We here used whole BMCs instead of an enriched stem cell fraction to avoid the loss of experimental animals




Fig. 1. Time course of GFP gene transferred cell ratio in peripheral blood cells (PBCs) after bone marrow transplantation (BMT). After bone marrow transplantation of  $2 \times 10^7$  BMCs treated with ts-rSeV/dF-GFP (BMT/ts-rSeV/dF-GFP,  $n = 10$ ) or conventional rSeV/dF-GFP (BMT/rSeV/dF-GFP,  $n = 9$ ), the PBCs were collected via the tail vein of C57BL/6 recipient mice at each time point, and GFP expression was determined by FACS analysis. BMCs from GFP-transgenic mice ( $n = 3$ ) were used as a positive control.

from unsuccessful reconstruction after lethal irradiation. BMCs were isolated from medullary cavities of tibiae and femurs. Erythrocytes were depleted in lysing buffer (0.38%  $\text{NH}_4\text{Cl}$  in Tris-HCl, pH 7.65) and mature T-lymphocytes were removed by anti-Thy1.2 antibody (mouse ascitis IgM monoclonal antibody) with rabbit complement; the removal of more than 99.9% of T-cells was constantly done and checked by FACS analysis. These BMCs were incubated with vectors at a multiplicity of infections 10 (MOI = 10) for only 1 h at 37 °C, and GFP expression was determined 48 h later, as described previously [15]. Both vectors constantly showed high gene transfer efficiency (>85%) to murine BMCs in repeated experiments (data not shown; similar data are shown in Fig. 2A).

Next, we engrafted these BMCs ( $2 \times 10^7$  cells/200  $\mu\text{l}$ /head, 1 h after virus exposure) to lethally irradiated ( $\gamma$ -X ray 10 Gy) female C57BL/6 mice via the tail vein, and then the GFP expression in the cells from peripheral blood (PBCs) was monitored every week. BMCs from  $\beta$ -actin promoter-driven GFP transgenic mice (C57BL/6-TgN(act-EGFP)Osbc14-Y01-FM131) [15] were also used as a positive control of successful bone marrow transplantation (BMT).

As shown in Fig. 1, all recipients receiving BMCs from GFP transgenic mice (GFP-TG) demonstrated nearly




Fig. 2. *In vitro* gene transfer efficiencies of ts-rSeV/dF-GFP to populations of hematopoietic stem cells (HSC) and common myeloid and lymphoid progenitors (CMPs and CLPs). A typical result of the FACS analyses is given as panels, and the summary of triplicate experiments is demonstrated in the bottom table. Each enriched population was gated by  $\text{Lin}^-/\text{c-Kit}^+/\text{Sca-1}^-$  for CMPs,  $\text{Lin}^-/\text{c-Kit}^{\text{low}}/\text{Sca-1}^{\text{low}}$  for CLPs, and  $\text{Lin}^-/\text{c-Kit}^{\text{high}}/\text{Sca-1}^{\text{high}}$  for HSCs. Data are expressed as mean  $\pm$  SD.

100% GFP-positive cells in PBCs, indicating successful engraftment of, and almost total replacement by, donor cells under this experimental condition. In contrast, PBCs from mice of BMT/rSeV/dF-GFP showed very low repopulation of GFP-positive cells (~1%) at 1 week, and were rapidly eliminated during the experimental course, a representative result of our previous experiments (unpublished data). Importantly, recipient mice with BMT/ts-rSeV/dF-GFP exhibited a relatively high repopulation of PBCs (50–70%) 1 week after BMT; the ratio gradually declined to ~10% at 4 weeks.

To our knowledge, this is the first demonstration of the efficient repopulation of donor cells that were transferred by cytoplasmic RNA vector.

*Efficient ts-rSeV/dF-mediated gene transfer to HSCs and progenitor populations*

We examined the gene transfer efficiencies of ts-rSeV/dF-GFP to common myeloid progenitors (CMPs: enriched in Lin<sup>-</sup>Sca-1<sup>-</sup>c-Kit<sup>+</sup>) [16], common lymphoid progenitors (CLPs: enriched in Lin<sup>-</sup>Sca-1<sup>low</sup>c-Kit<sup>low</sup>) [17], and HSCs (enriched in Lin<sup>-</sup>Sca-1<sup>high</sup>c-Kit<sup>high</sup>) by flow-cytometric analysis (Fig. 2). Constant high gene transfer, over 90%, was seen in T-cell-depleted BMCs by ts-rSeV/dF-GFP, and relatively high gene transfer also occurred in these populations (mean = 97.5% of CMPs, 77.3% of CLPs, and 63.9% in HSCs, n = 3).

*Multilineage differentiation of cytoplasmically gene transferred HSCs in vitro*

Subsequently, we investigated whether gene transferred HSCs by ts-rSeV/dF-GFP might sufficiently differentiate to various types of colonies by a colony-forming assay. As shown in Fig. 3, 1000 cells of highly enriched HSCs were sorted from BMCs twice and transfected with the GFP gene, and then sparsely cultured for 12 days [16]. Colony-forming units (CFU) were then assessed by fluorescence microscope. We counted the number of multilineage mixed colonies (CFU-Mix) as CFU from single cells with pluripotency. The result in Fig. 3 shows, a reduction in the number of CFU-Mix was not seen in cells treated with ts-rSeV/dF-GFP, suggesting no significant effect of gene transduction to cell differentiation. In addition, the ratio of GFP-positive colonies was almost comparable to gene transfer efficiency to HSCs, suggesting no significant effect on cell growth by ts-rSeV/dF-GFP, at least *in vitro*.

*In vivo repopulation and multilineage differentiation of cytoplasmically gene transferred BMCs*

Using six animals 5 weeks after BMT with BMC treated ts-rSeV/dF-GFP, we next examined the distribution, repopulation and differentiation of GFP-positive cells in typical lymphoid organs (thymus, spleen, bone marrow)




Fig. 3. *In vitro* colony-formation assay. Cells were sorted twice (FACS panels) in order to enrich HSC fraction, a typical photomicrograph of GFP-positive CFU-Mix (bottom left), suggesting multilineage differentiation, and the table summary of the quantitative data (bottom right) are given. Data are expressed as mean ± SD.

as well as PBCs by flow cytometry. As shown in Fig. 4A, these six mice showed a representatively high GFP-positive ratio ( $55.9 \pm 5.9\%$ ,  $n = 6$ ) in PBCs, and the thymus, spleen, and bone marrow of these animals also exhibited a mean = 47.7%, 79.3% and 17.1% of GFP-positive cells, respectively, confirming the repopulation of transplanted cells in each lymphoid organ. A simultaneous experiment using the BMT/SeV/dF-GFP of three animals did not show any GFP-positive cells at all 5 weeks after BMT (data not shown).

Subsequently, we investigated the GFP-positive ratio of each cell type in the spleen and bone marrow by FACS analyses. Cells from each organ were determined by antibodies specific for the following surface-markers: NK cells =  $CD3^-/DX5^+$ , NKT cells =  $CD3^+/DX5^+$ , pan-T-cells =  $CD3^+/DX5^-$ , CD4/T-cells =  $CD3^+/CD4^+$ , CD8/T-cells =  $CD3^+/CD8^+$ , dendritic cells (DCs) =  $CD11b^+/CD11c^+$ , monocytes/macrophages ( $M\phi$ ) =  $CD11b^+/CD11c^-$ , B-cells =  $B220^+/IgM^+$ . As shown in Fig. 4B, even though BMCs were used after complete depletion of T-

cells, all these subsets contained GFP-positive cells at various ratios including T-cell lineages, suggesting that these GFP-positive cells were from HSCs and progenitors. Interestingly, DCs and  $M\phi$ s, both from CMPs [16], included a relatively large number of GFP-positive cells in both the spleen and bone marrow, probably reflecting the high gene transfer to CMPs (Fig. 2).

These findings, therefore, strongly suggested that BMCs transfected with ts-rSeV/dF-GFP were capable of differentiating the whole hematopoietic series *in vivo*.

## Discussion

Physicians and scientists in the gene therapy community have been greatly encouraged by the dramatic outcome of clinical studies to treat X-linked SCID conducted in France [1]. However, this trial has also raised safety concerns about vector integration to the host chromosomes.

Using vectors that express the transgene in cellular cytoplasm is one possible way of addressing safety concerns; in the present study, therefore, we attempted to seek the potential of a cytoplasmic RNA vector, rSeV, as a new modality for gene therapy to treat hematopoietic disorders. To the best of our knowledge, this is the first study to make use of a newly developed version of the cytoplasmic RNA vector, ts-rSeV/dF, to show the high gene transfer efficiency to hematopoietic stem/progenitor populations and their successful repopulation associated with differentiation to multiple lineages of hematopoietic series.

Apparently, an advance seen in this study is that the repopulation of cytoplasmically gene transferred BMCs could be done by using an improved design of rSeV/dF, a temperature-sensitive mutant ts-rSeV/dF, but not of conventional rSeV/dF (and prototype additive rSeV, unpublished data). However, there is no definitive explanation as to why ts-rSeV/dF realized an efficient repopulation. As previously demonstrated, ts-rSeV/dF shows a reduced cytotoxic effect on some types of cells, but this is not a likely explanation for its ability to realize BMC repopulation because our *in vitro* study using murine HSCs, which is shown in Fig. 3, along with a previous study using human HSCs [11], could not demonstrate the apparent cytotoxicity and the disturbance of their differentiation caused by any type of rSeV vector. It is therefore possible that the reduced expression of HN protein due to the insertion of temperature-sensitive mutations enabled BMCs to repopulate in the recipient.

The findings obtained in this study suggested the possible application of 'cytoplasmic gene therapy' for hematopoietic disorders; however, our preliminary study assessing long-term engraftment also revealed the potential limitations of the current construct *in vivo* in view of its clinical application. In other words, more than 40% of recipient mice showing efficient hematopoietic gene transfer were dead in later phase due to severe pancytopenia (Yoshida K and Yonemitsu Y, unpublished data), therefore, more studies and biological information are thus




Fig. 4. *In vivo* repopulation and multilineage differentiation of BMCs transfected by ts-rSeV/dF-GFP after BMT. Data are expressed as mean  $\pm$  SD. (A) Repopulation efficiency of ts-rSeV/dF-GFP treated BMCs in typical lymphoid organs at 4 weeks after BMT *in vivo*. (B) FACS analysis of ration of GFP expression in various cellular subsets in spleen and bone marrow of recipient mice at 5 weeks after BMT. Each cell subset was determined as follows: NK =  $CD3^-/DX5^+$ , NKT =  $CD3^+/DX5^+$ , pan-T-lymphocytes =  $CD3^+/DX5^-$ , CD4/T-cells =  $CD3^+/CD4^+$ , CD8/T-cells =  $CD3^+/CD8^+$ , DCs =  $CD11b^+/CD11c^+$ ,  $M\phi$  =  $CD11b^+/CD11c^-$ , and B-lymphocytes =  $B220^+/IgM^+$ .

needed to realize cytoplasmic gene therapy for hematopoietic diseases.

In summary, we here demonstrated the successful repopulation and reconstruction of hematopoietic series by cytoplasmically gene transferred BMCs using newly developed ts-rSeV/dF. This study is, to the best of our knowledge, the first report reconstituting whole hematopoietic series using a bone marrow gene transferred by cytoplasmic transcription, but the transient repopulation is an issue that must be resolved. Since 'cytoplasmic gene therapy' is an attractive and challenging strategy for physicians and scientists in this field, further studies are needed to overcome the current problems.

#### Competing interest statement

Dr. Yonemitsu is a member of the Scientific Advisory Board of DNAVEC Corporation.

#### Acknowledgments

The authors thank Drs. Mariko Yoshizaki, Akihiro Tagawa, Takumi Kanaya, Hiroshi Ban, and Takashi Hirouka for their excellent technical assistance with the construction and large-scale production of rSeV vectors, and Ms. Chie Arimatsu for her invaluable help with the animal experiments.

#### References

- [1] M. Cavazzana-Calvo, S. Hacein-Bey, G. de Saint Basile, F. Gross, E. Yvon, P. Nusbaum, F. Selz, C. Hue, S. Certain, J.L. Casanova, P. Bousso, F.L. Deist, A. Fischer, Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, *Science* 288 (2000) 669–672.
- [2] J. Kaiser, Gene therapy. Seeking the cause of induced leukemias in X-SCID trial, *Science* 299 (2003) 495.
- [3] S. Hacein-Bey-Abina, C. Von Kalle, M. Schmidt, M.P. McCormack, N. Wulffraat, P. Leboulch, A. Lim, C.S. Osborne, R. Pawliuk, E. Morillon, R. Sorensen, A. Forster, P. Fraser, J.I. Cohen, G. de Saint Basile, I. Alexander, U. Wintergerst, T. Frebourg, A. Aurias, D. Stoppa-Lyonnet, S. Romana, I. Radford-Weiss, F. Gross, F. Valensi, E. Delabesse, E. Macintyre, F. Sigaux, J. Soulier, L.E. Leiva, M. Wissler, C. Prinz, T.H. Rabbitts, F. Le Deist, A. Fischer, M. Cavazzana-Calvo, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, *Science* 302 (2003) 415–419.
- [4] A. Fischer, S.H. Abina, A. Thrasher, C. von Kalle, M. Cavazzana-Calvo, LMO2 and gene therapy for severe combined immunodeficiency, *N. Eng. J. Med.* 350 (2004) 2526–2527.
- [5] Y. Yonemitsu, C. Kitson, S. Ferrari, R. Farley, U. Griesenbach, D. Judd, R. Steel, P. Scheid, J. Zhu, P.K. Jeffery, A. Kato, M.K. Hasan, Y. Nagai, I. Masaki, M. Fukumura, M. Hasegawa, D.M. Geddes, E.W. Alton, Efficient gene transfer to airway epithelium using recombinant Sendai virus, *Nat. Biotechnol.* 18 (2000) 970–973.
- [6] I. Masaki, Y. Yonemitsu, K. Komori, H. Ueno, Y. Nakashima, K. Nakagawa, M. Fukumura, A. Kato, M.K. Hasan, Y. Nagai, K. Sugimachi, M. Hasegawa, K. Sueishi, Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system, *FASEB J.* 15 (2001) 1294–1296.
- [7] A. Yamashita, Y. Yonemitsu, S. Okano, K. Nakagawa, Y. Nakashima, Y. Iwamoto, Y. Nagai, M. Hasegawa, K. Sueishi, Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats, *J. Immunol.* 168 (2002) 450–457.
- [8] I. Masaki, Y. Yonemitsu, A. Yamashita, S. Sata, M. Tani, K. Komori, K. Nakagawa, X. Hou, Y. Nagai, M. Hasegawa, K. Sugimachi, K. Sueishi, Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of VEGF165, but not of FGF-2, *Circ. Res.* 90 (2002) 966–973.
- [9] H.O. Li, Y.F. Zhu, M. Asakawa, H. Kuma, T. Hirata, Y. Ueda, Y.S. Lee, M. Fukumura, A. Iida, A. Kato, Y. Nagai, M. Hasegawa, A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression, *J. Virol.* 74 (2000) 6564–6569.
- [10] S.A. Moyer, S.C. Baker, J.L. Lessard, Tubulin: a factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs, *Proc. Natl. Acad. Sci. USA* 83 (1986) 5405–5409.
- [11] C.H. Jin, K. Kusuohara, Y. Yonemitsu, A. Nomura, S. Okano, H. Takeshita, M. Hasegawa, K. Sueishi, T. Hara, Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells, *Gene Ther.* 10 (2003) 272–277.
- [12] M. Inoue, Y. Tokusumi, H. Ban, T. Kanaya, T. Tokusumi, Y. Nagai, A. Iida, M. Hasegawa, Nontransmissible virus-like particle formation by F-deficient Sendai virus is temperature sensitive and reduced by mutations in M and HN proteins, *J. Virol.* 77 (2003) 3238–3246.
- [13] M. Inoue, Y. Tokusumi, H. Ban, A. Kato, Y. Nagai, A. Iida, M. Hasegawa, Further attenuation of gene(s)-deleted Sendai virus vectors: modification of transcription and replication caused weakened cytotoxicity, *Mol. Ther.* 7 (Suppl.) (2003) S37 (Abstract).
- [14] S. Tanaka, Y. Yonemitsu, K. Yoshida, S. Okano, H. Kondo, M. Inoue, M. Hasegawa, K. Masumoto, S. Suita, T. Taguchi, K. Sueishi, Impact of deletion of membranous genes of recombinant Sendai viruses on immune responses following pulmonary gene transfer of neonatal mice, *Gene Ther.* 14 (2007) 1017–1028.
- [15] R.I. Kohno, Y. Ikeda, Y. Yonemitsu, T. Hisatomi, M. Yamaguchi, M. Miyazaki, H. Takeshita, T. Ishibashi, K. Sueishi, Sphere formation of ocular epithelial cells in ciliary body is a reprogramming system for neural differentiation, *Brain Res.* 1093 (2006) 54–70.
- [16] K. Akashi, D. Traver, T. Miyamoto, I.L. Weissman, A clonogenic common myeloid progenitor that gives rise to all myeloid lineages, *Nature* 404 (2000) 193–197.
- [17] M. Kondo, I.L. Weissman, K. Akashi, Identification of clonogenic common lymphoid progenitors in mouse bone marrow, *Cell* 91 (1997) 661–672.



## Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells <sup>☆</sup>

Yasuo Yoneyama <sup>a,b</sup>, Yasuji Ueda <sup>a</sup>, Yasunori Akutsu <sup>b</sup>, Akinao Matsunaga <sup>a,b</sup>,  
Hideaki Shimada <sup>b</sup>, Tomonori Kato <sup>a,c</sup>, Megumi Kubota-Akizawa <sup>a,b</sup>, Shinji Okano <sup>d</sup>,  
Satoko Shibata <sup>d</sup>, Katsuo Sueishi <sup>d</sup>, Mamoru Hasegawa <sup>e</sup>, Takenori Ochiai <sup>b</sup>,  
Yoshikazu Yonemitsu <sup>a,d,\*</sup>

<sup>a</sup> Department of Gene Therapy, Chiba University, Chiba, Japan

<sup>b</sup> Department of Frontier Surgery, Chiba University, Chiba, Japan

<sup>c</sup> Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan

<sup>d</sup> Department of Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

<sup>e</sup> DNAVEC Corporation, Tsukuba, Ibaraki, Japan

Received 20 January 2007

Available online 2 February 2007

### Abstract

Dendritic cell (DC)-based immunotherapy has been clinically evaluated, however, still requires modification to improve its outcomes. We previously demonstrated that DCs activated by replication competent recombinant Sendai virus (SeV) showed dramatic efficacy over that seen in use of current DC vaccine for immunotherapy against malignancies; however, application of replication-deficient vector is more relevant in clinical setting. We here show that F-gene-deleted non-transmissible Sendai virus (SeV/dF)-activated DCs (DCs/SeV/dF) has strong antitumor effects against murine SCCVII tumor, that was well-known as a less immunogenic cell line. SeV/dF shows high transfection efficiency to DCs and leads them to upregulate costimulatory molecules. Intratumoral injection of DCs/SeV/dF resulted in a marked and representative inhibition of the tumor, even when the tumors were well-vascularized. This is the first demonstration that non-transmissible SeV vector, SeV/dF, could be a DC-activator; DC/SeV/dF-based cancer immunotherapy may, therefore, warrant further investigation.

© 2007 Elsevier Inc. All rights reserved.

**Keywords:** Squamous cell carcinoma; Non-transmissible Sendai virus; Dendritic cell

Despite the continuous efforts of physicians, the overall survival for patients with squamous cell carcinoma (SCC), including esophageal cancers, have not shown significant improvement over the last decade [1,2]. Among the clinically available therapeutics, surgical treatment has been the most effective when cancer foci could be resected without the involvement of or metastasis to other vital organs [3–5].

However, in the case of esophageal carcinomas, anatomical loss of serosa of the esophagus would be a cause of accelerated invasiveness of SCC to the aorta, trachea, etc., resulting in advanced diseases. Extensive surgical approaches, including extended esophagectomy with 3-field lymph node dissection could improve patient prognosis, but quality of life is occasionally reduced due to impairment of deglutition, phonation, and respiration [3,4]. Since such advanced esophageal SCC has also remained intractable to chemo-radiotherapy, the development of novel and less invasive therapeutic strategies has been much desired to treat patients with advanced SCC.

<sup>☆</sup> *Competing interest statement:* The authors declare that they have no competing financial interests.

\* Corresponding author. Fax: +81 43 226 2973.

E-mail address: [yonemitu@faculty.chiba-u.jp](mailto:yonemitu@faculty.chiba-u.jp) (Y. Yonemitsu).

Much attention has been paid to cancer immunotherapy using dendritic cells (DCs) that has shown good potential for antitumor immunity [6,7]; DC-based cancer immunotherapy is, therefore, currently being tested in clinical trials all over the world. Although reported clinical trials have shown the safety and feasibility of DC therapy in patients bearing advanced malignancies, objective clinical responses have remained limited [8,9].

The poor clinical response of DC therapy might be due to the insufficient activation, and, in turn, the state of activation of DCs for cancer vaccine is still under debate [10]. Immature DCs (iDCs) display a phenotype reflecting their specialized function as antigen-capturing cells; however, the activity of antigen presentation of this subset of DCs to T cells, however, is not efficient [10]. Thus, to achieve a dramatic improvement in the clinical efficacy of DC-based cancer immunotherapy, knowledge regarding the most appropriate condition of DCs for cancer immunization should be obtained.

Sendai virus (SeV) is a negative-strand RNA virus and a member of the *paramyxoviridae* family, and the genomic replication and transcription are carried out in the cytoplasm by its own RNA polymerase. Using a prototype vector based on SeV, replication competent SeV, we recently demonstrated that DCs activated by SeV showed dramatically enhanced antitumor effects on various murine tumors [11], suggesting the possible utility of SeV vector system for cancer immunotherapy. As a next step, we subsequently developed a new mode of non-transmissible viral vector based on SeV-lacking fusion (F) gene (SeV/dF) that is more relevant for clinical use [12]. Some previous observations have demonstrated that immature DCs are dramatically activated and leads to a maturation state by the infection of SeV, thus acquiring the capacity to promote cell-mediated immunity in a replication-dependent and toll-like receptor (TLR)-independent fashion [13,14].

We, therefore, investigated the therapeutic value and immune consequences of intratumoral administration of activated DCs by SeV/dF.

## Methods

**Mice and cell line.** Female C3H/He mice (6–7 weeks old) were purchased from Shizuoka Laboratory Animal Center (Hamamatsu, Shizuoka, Japan) and kept under specific pathogen-free conditions. All animal experiments were performed according to approved protocols and in accordance with recommendations for the proper care and use of laboratory animals by the Committee for Animals, Recombinant DNA, and Experiments Using Infectious Pathogens at Chiba University, and according to The Law (No. 105) and Notification (No. 6) of the Japanese Government. SCCVII (kindly provided by Dr. Shibamoto, Nagoya City University) is a spontaneously arising murine SCC that has been shown to be poorly immunogenic [15].

**Rescue of SeV/dF.** Preparation and recovery of F-defective and non-transmissible recombinant SeV used in this study (SeV/dF-GFP and SeV/dF-null) were performed as previously described [12,16]. Briefly, LLC-MK2 cells stably expressing F-gene were transfected with a plasmid mixture containing pSeV18+b(+)/F-EGFP, pGEM-NP, pGEM-P, and

pGEM-L. The transfected cells were collected, resuspended, and lysed by three cycles of freezing and thawing. Subsequent genomic RNA–nuclear protein complex (RNP) transfection was performed by cationic lipid into F-expressing LLC-MK2/F7 cells. Virus yield is expressed in PFU and cell infectious units (CIU).

**Murine bone marrow-derived DCs (mBM-DCs).** DCs were obtained from mouse bone marrow precursors as described previously [11,17] with minor modification. Briefly, bone marrow cells were harvested from femurs and tibias. After washing, lineage antigen-positive (CD45R, CD5, CD11b, Gr-1, TER119, 7/4) cells were removed by using the SpinSep mouse hematopoietic progenitor enrichment kit (StemCell technologies, Canada). These lineage-negative cells were cultured under 20 ng/ml murine GM-CSF and 20 ng/ml murine IL-4 in RPMI 1640 medium. On day 4, the cultures were refreshed by adding a half volume of culture medium supplemented with GM-CSF and IL-4 at the same concentrations. On day 7, DCs were collected and seeded at  $1 \times 10^6$ /ml and then incubated with SeV vectors at each MOI or lipopolysaccharide (LPS) (1  $\mu$ g/ml).

**Flow cytometric analysis.** DCs were replated in fresh medium and incubated with SeV-GFP at each MOI or 1  $\mu$ g/ml LPS for 48 h. Biotin-conjugated anti-mouse H-2K, CD40, CD80, CD86, and FITC-conjugated anti-CD11c (Pharmingen, San Diego, CA) monoclonal antibodies (mAbs) were used for each primary antibody, and biotinylated Abs were detected by subsequent staining with streptavidin-PE (Pharmingen). Cells were analyzed using a FACScalibur (Becton–Dickinson Tokyo, Japan).

**Cytotoxic assay.** DCs were replated and incubated with SeV/dF-GFP at each MOI. At 48 h, cell viability was assessed with 7-amino-actinomycin D (7AAD) to count living cells for FACS analysis, as previously described [18].

**Fluorescein isothiocyanate (FITC)–dextran uptake.** FITC–dextran uptake was performed to assess the endo-/phagocytotic activity of DCs. Cells were then incubated with 1 mg/ml of FITC–dextran (MW = 40,000, Sigma–Aldrich, Tokyo, Japan) for 30 min at 4 or 37 °C, and washed with ice-cold phosphate-buffered saline (PBS) and labeled on ice with PE-conjugated mAb for CD11c. The uptake was measured by FACS at different times after stimulation, and was calculated as the change in MFI between cell samples incubated at 37 and 4 °C.

**DC immunotherapy of the established tumor.** SCCVII cells were harvested and processed by three rapid cycles of freezing and thawing. DCs were pulsed with tumor lysate (DC number: number of tumor cells for lysate = 1:3) for 18 h and were then incubated with SeV/dF or LPS for 8 h. Intradermal implantation was performed in the abdomen on day 0, and  $1 \times 10^6$  DCs were injected intratumorally on days 10, 17, and 24. For all injections, materials were suspended in a 100- $\mu$ l volume of PBS. The tumor size was assessed using microcalipers three times a week, and the volume was calculated by the following formula: (tumor volume;  $\text{mm}^3$ ) =  $0.5236 \times (\text{long axis}) \times (\text{short axis}) \times (\text{height})$ .

**Immunohistochemical staining.** Standard immunohistochemical staining was performed using 5- $\mu$ m-thick paraffin-embedded sections by standard avidin–biotin complex method. Blocking was done using 3% hydrogen peroxide and non-immune serum, and the primary antibodies (anti-vWF, Chemicon international, CA) was applied for 1 h at room temperature. Visualization was done using 3,3-diaminobenzidine substrate solution, and the sections were counter-stained with hematoxylin.

**CTL activity.** Seven days after the last immunization, spleen cells were pooled, and restimulated with irradiated (100 Gy) SCCVII cells for 6 days. These cells were harvested on day 6 and used as effector cells in a standard 4-h  $^{51}\text{Cr}$  release assay. Target tumor cells ( $1 \times 10^6$ ) were labeled with 100  $\mu\text{Ci}$  of  $\text{Na}_2^{51}\text{CrO}_4$  for 90 min at 37 °C. The labeled target cells were incubated with the effector cells for 4 h at 37 °C in 96-well plates in 200  $\mu\text{l}$  of T-cell medium at various E:T ratios. The radioactivity of the supernatants was counted using a  $\gamma$ -counter. Cytolytic activity was calculated using the following formula: percentage of specific  $\text{Cr}^{51}$  release = (experimental release – spontaneous release)  $\times$  100/(maximum release – spontaneous release). Assays were performed in triplicated wells.

**Statistical analysis.** The data were evaluated statistically by repeated measures one-way ANOVA. The statistical significance of difference groups was determined using the Scheff's test, and  $P < 0.05$  was considered statistically significant.



## Results

### Characterization of DCs modified by SeV/dF

DCs infected by SeV/dF-GFP at each MOI were analyzed by flow cytometry for GFP expression. The ratio of GFP-expressing DCs increased in a MOI-dependent manner, with the transfection efficiency at MOI = 20 being estimated at approximately 80% based on similar findings in repeated experiments (Fig. 1A). Interestingly, LPS-activation of DCs reduced the transfection efficiency of SeV/dF-GFP (data not shown), indicating that the susceptibility of mBM-DCs to SeV/dF may depend on their maturation state. Higher viral doses of SeV/dF-GFP did not result in a significant cytopathic effect (Fig. 1A).

### Phenotype of mBM-DCs treated by SeV/dF

We next evaluated the effects of SeV/dF transfection on the maturation and activation of DCs. Here, we used SeV/dF without a foreign gene (SeV/dF-null).

Two-day stimulation of iDCs with SeV/dF-null or LPS, a well-known strong DC-activator that is not clinically available, increased the expression of these costimulatory molecules. The expression levels of surface markers on the C3H strain-derived DCs after SeV/dF-null infection were milder than for those treated with LPS (Fig. 1B); a different finding indicating that C57BL6-derived DC/SeV/dF-null show comparable levels of expression to those seen with LPS [11].

We subsequently assessed the effects of SeV/dF on endo-/phagocytotic activity of mBM-DCs as compared with that of LPS (Fig. 1C). Endo-/phagocytosis of DC/LPS was mildly and transiently enhanced, peaked at 1 h after LPS stimulation, and then markedly downregulated in its time course. In contrast, endo-/phagocytosis of DC/SeV/dF-null was transiently decreased, and then caught up to levels comparable to those of immature DCs. Forty-eight hours after stimulation, the endo-/phagocytotic activity of DCs-SeV/dF-null was significantly higher than that of DC/LPS ( $P < 0.05$ ,  $n = 4$ , each), which was equal to the levels of unstimulated DCs.

These results suggest that SeV/dF-null may activate mBM-DCs without any significant reduction in their endo-/phagocytotic activity.

### Antitumor effects of SeV-activated DC *in vivo*

We next examined the antitumor effects of intratumoral administration of DCs activated with SeV/dF *in vivo*. We here used established (7–10 mm in diameter on day 10) and well-vascularized SCCVII tumors (Fig. 2A); because 'there are no cancer vaccine models that reproducibly demonstrate that vascularized tumors can be rejected' at present, as noted by Rosenberg et al. [9].

Tumor-bearing mice were given tumor lysate-pulsed mBM-DCs which were activated with LPS or SeV/dF-GFP three times (Fig. 2B and C). Administration of DCs

without stimulation showed a modest antitumor response, probably due to their mild spontaneous activation during *ex vivo* cultivation. Antitumor activity was significantly enhanced with the use of DCs/LPS, and one animal showed a complete rejection of the tumor. Intratumoral injection of DCs/SeV/dF resulted in a marked inhibition of tumor growth in all animals, and with this regimen, 2 of 7 tumors were completely eliminated, a finding determined by histopathology.

Next, the cytolytic activity of spleen cells was investigated. Cytolytic activity against SCCVII cells was augmented in unstimulated DCs, DC/LPS, and the DCs/SeV/dF treatment group compared with that in the no-treatment groups (Fig. 3). The highest cytolytic activity was observed in the mice that received DCs/SeV/dF treatment.

These results confirmed that intratumoral injection of DCs/SeV/dF enhanced the tumor-specific CTL response.

### Antitumor effects of SeV-activated DC without pulsing tumor lysate

As shown in Fig. 1, endo-/phagocytosis of DCs was not impaired by SeV/dF treatment *in vitro*; we, therefore, evaluated the antitumor effects of SeV-activated DCs without pretreatment with tumor lysate. As shown in Fig. 4, the antitumor effects of DCs activated by SeV/dF were not impaired without pulsing tumor lysate, whereas no tumor showed complete elimination. These results suggest that intratumoral injection of DC/SeV/dF may not always require the uptake of tumor antigen during preparation.

## Discussion

The key observations of the current study were as follows: (1) SeV/dF efficiently transfected immature mBM-DCs without a significant reduction of cell viability; (2) SeV/dF leads mBM-DCs to a mature and activated state without a significant reduction in endo-/phagocytotic activity; (3) DC/SeV/dF-GFP demonstrates superior antitumor effects on less immunogenic murine SCCs, which were treated as well-established and well-vascularized, in comparison with the use of DC/LPS. This is the first report suggesting the potential utility of SeV/dF as an alternative activator for DCs in clinical cancer immunotherapy.

We demonstrate that SeV/dF efficiently transfects DCs at relatively lower MOI without significant cytopathic effects. Although other investigators have focused on adenovirus vectors for gene transfer to DCs, much higher titer (over MOI = 300) has been required [19,20] to achieve the comparable efficiency of SeV at lower MOI. It has been reported that adenoviral infection induces cytotoxicity and impairs antigen uptake [20], although there are some conflicting reports regarding this point. iDCs actively internalize antigen, and in contrast, mature DCs are poorly endocytotic and function to present antigens to T-cells [21,22]. Our findings, however, have demonstrated that DCs activated by SeV/dF can efficiently uptake antigens




Fig. 1. Characterization of mBM-DCs modified by SeV/dF. (A) Gene transfer efficiency and cytopathic effects. Forty-eight hours after SeV/dF-GFP exposure, DCs were subjected to FACS analysis assessing the gene transfer efficiency (left), or to an assessment of cell viability by an early apoptotic cell-detecting technique using 7AAD (right). These experiments were performed at least in duplicate, and all produced similar results. (B) Effects of SeV/dF on surface markers of mBM-DCs. DCs were collected and transfected by SeV/dF-null at MOI = 40 or exposed to LPS (1  $\mu$ g/ml), and 48 h later, DCs were subjected to FACS analysis assessing the expression of surface markers. Bar graph indicating the corresponding mean fluorescent intensity (MFI) is shown. The experiment was carried out in triplicate, producing similar results. (C) Effects of SeV/dF on endo-/phagocytic activities of mBM-DCs. DCs were transfected by SeV/dF-null at MOI = 40 or stimulated by LPS (1  $\mu$ g/ml), and then exposed to 1 mg/ml of FITC-dextran for 30 min at 4 or 37  $^{\circ}$ C. The uptake was measured at each time and expressed MFI between cell samples incubated at 37 and 4  $^{\circ}$ C. The graph contains all data from four independent experiments using the same procedure.

and that the antitumor effects of DC/SeV/dF via intratumor injection were not impaired without pulsing tumor lysate, suggesting that the DC/SeV/dF may still have antigen uptake and processing activity *in vivo*.

Despite the higher expression of costimulatory molecules, CD40, CD80, and CD86 in DC/LPS than in DC/SeV/dF, the intratumor administration of DCs/SeV to established SCCVII tumors *in vivo* showed stronger antitu-




Fig. 2. Antitumor effects of intratumor administration of lysate-pulsed DC/SeV/dF-GFP against well-vascularized SCCVII tumors. (A) Characterization of the established SCCVII tumors at the time of the start of DC-therapy. Left: representative gross observation of intradermally inoculated SCCVII tumor of C3H mice. The size of the tumor is 7–10 mm in diameter. Middle and right (original magnification: 200 $\times$ ): histopathological findings in hematoxylin-eosin (H.E.; middle) and in immunohistochemistry for von Willebrand Factor (IHC-vWF) identifying intratumor neovascularization (arrows). (B) The time course of tumor volume of each animal. Ten days after tumor inoculation, DC-therapy (left upper: no treatment; right upper: DCs without stimulant; left bottom: DCs activated with LPS; and right bottom: DCs activated with SeV/dF-GFP) was performed three times at weekly intervals (indicated as arrows). One animal of the DC/LPS group and 2 of the DC/SeV/dF-GFP were completely eliminated. (C) Bar graph providing a direct comparison of tumor volume on day 30.




Fig. 3. Cr release assay to determine the CTL activity. Seven days after the third immunization, spleen cells isolated from immunized mice and  $^{51}\text{Cr}$  release assay was performed.

mor effects and CTL activity than that of DC/LPS. The exact reason for these stronger effects remain unknown, but a possible mechanism related to the continuity of activity of DCs can be explained as follows. Recent studies related to the activity of DCs have shown that DCs exposed to stimuli for long periods undergo functional paralysis or exhaustion [23,24]. Considering the maintained endocytotic activity and modest upregulation of costimulatory molecules on DC/SeV, it may be possible that the paralysis or exhaustion of DC/LPS expressing higher surface markers resulted in more modest antitumor effects than those seen in the use of DC/SeV/dF.

Related to the above discussion, several important studies regarding the mechanisms of negative-strand RNA

virus-induced activation of DCs have been reported in recent years. These are categorized as having two independent systems, namely toll-like receptors (TLRs) and TLR-independent systems; the former recognize dsRNA and ssRNA presuming pathogen-associated molecular patterns for viruses [25], and the latter is a TLR-independent pathway using RNA helicases, including RIG-I [26]. The latter pathway well explains that activated DCs by SeV are more powerful than DCs that are exposed to LPS *in vivo*; therefore, further characterization should provide a better understanding of the mechanism to improve the efficacy of cancer vaccines.

Immunotherapy for SCCs has not been well-studied, and there is at present sparse information regarding the response of SCCs to CTLs. Although previous experimental studies demonstrated that the pre-administration of lymphokine-activated killer cells prevented pulmonary metastases of SCCVII cells, which are a less immunogenic cell line used in this study, they have not demonstrated any significant reduction in established pulmonary metastases [15,27]. Since 'there are no cancer vaccine models that reproducibly demonstrate that vascularized tumors can be rejected' at present, as noted by Rosenberg et al. [9,28], the current results, indicating that the well-vascularized tumors were eliminated in more than 25 % of mice treated with DC/SeV/dF-GFP, suggest the potential utility of DC/SeV/dF.

In summary, we here demonstrated that mBM-DCs treated with non-transmissible SeV/dF without therapeutic




Fig. 4. The time course of tumor volume of each animal in response to DC-therapy without *ex vivo* tumor lysate pulsing. DC-therapy without pulse (upper: no treatment; left bottom: DC/LPS; and right bottom: DC/SeV/dF-GFP) was performed three times at weekly intervals from 10 days after tumor inoculation.

gene induced strong antitumor effects against less immunogenic murine SCC tumors. These results thus indicate for the first time that SeV/dF could be a promising candidate for DC-activator to treat intractable malignancies; therefore, DC/SeV/dF warrants further investigation for enhancing antitumor effects in a clinical setting.

### Acknowledgments

This work was supported in part by a Grant of the 21st Century Center of Excellence (COE) Program at Chiba University and a Grant-in-Aid from the Japanese Ministry of Education, Culture, Sports, Science and Technology.

### References

- [1] J. Bernier, J.S. Cooper, Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? *Oncologist* 10 (2005) 215–224.
- [2] R.A. Malthaner, R.K. Wong, R.B. Rumble, L. Zuraw, Members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care, Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis, *BMC Med.* 2 (2004) 35.
- [3] K. Isono, S. Onoda, T. Ishikawa, H. Sato, K. Nakayama, Studies on the causes of deaths from esophageal carcinoma, *Cancer* 49 (1982) 2173–2179.
- [4] K. Isono, H. Sato, K. Nakayama, Results of a nationwide study on the three-field lymph node dissection of esophageal cancer, *Oncology* 48 (1991) 411–420.
- [5] M. Tachibana, S. Kinugasa, H. Yoshimura, M. Shibakita, Y. Tonomoto, D.K. Dhar, N. Nagasue, Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma, *Am. J. Surg.* 189 (2005) 98–109.
- [6] W. Song, R. Levy, Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells, *Cancer Res.* 65 (2005) 5958–5964.
- [7] S.E. Strome, S. Voss, R. Wilcox, T.L. Wakefield, K. Tamada, D. Flies, A. Chapoval, J. Lu, J.L. Kasperbauer, D. Padley, R. Vile, D. Gastineau, P. Wettstein, L. Chen, Strategies for antigen loading of dendritic cells to enhance the antitumor immune response, *Cancer Res.* 62 (2002) 1884–1889.
- [8] J. Banchereau, A.K. Palucka, Dendritic cells as therapeutic vaccines against cancer, *Nat. Rev. Immunol.* 5 (2005) 296–306.
- [9] S.A. Rosenberg, J.C. Yang, N.P. Restifo, Cancer immunotherapy: moving beyond current vaccines, *Nat. Med.* 10 (2004) 909–915.
- [10] M.B. Lutz, G. Schuler, Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? *Trends Immunol.* 23 (2002) 445–449.
- [11] S. Shibata, S. Okano, Y. Yonemitsu, M. Onimaru, S. Sata, H. Nagata-Takeshita, M. Inoue, M. Hasegawa, Y. Moroi, M. Furue, K. Sueishi, Induction of efficient antitumor immunity using dendritic cells activated by Sendai virus and its modulation of exogenous interferon- $\beta$  gene, *J. Immunol.* 177 (2006) 3564–3576.
- [12] H.O. Li, Y.F. Zhu, M. Asakawa, H. Kuma, T. Hirata, Y. Ueda, Y.S. Lee, M. Fukumura, A. Iida, A. Kato, Y. Nagai, M. Hasegawa, A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression, *J. Virol.* 74 (2000) 6564–6569.
- [13] C.B. Lopez, A. Garcia-Sastre, B.R. Williams, T.M. Moran, Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses, *J. Infect. Dis.* 187 (2003) 1126–1136.
- [14] C.B. Lopez, B. Moltedo, L. Alexopoulou, L. Bonifaz, R.A. Flavell, T.M. Moran, TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses, *J. Immunol.* 173 (2004) 6882–6889.
- [15] D. Khurana, E.A. Martin, J.L. Kasperbauer, B.W. O'Malley Jr., D.R. Salomao, L. Chen, S.E. Strome, Characterization of a spontaneously arising murine squamous cell carcinoma (SCCVII) as a prerequisite for head and neck cancer immunotherapy, *Head Neck* 23 (2001) 899–906.
- [16] T. Hirata, A. Iida, T. Shiraki-Iida, K. Kitazato, A. Kato, Y. Nagai, M. Hasegawa, An improved method for recovery of F-defective Sendai virus expressing foreign genes from cloned cDNA, *J. Virol. Methods* 104 (2002) 125–133.
- [17] K. Inaba, M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, R.M. Steinman, Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor, *J. Exp. Med.* 176 (1992) 1693–1702.
- [18] O. Haurat, P. Colombat, J. Domenech, M. Degenne, J.L. Bremond, L. Sensebe, M.C. Bernard M, C. Binet, A rapid single-laser flow cytometric method for discrimination of early apoptotic cells in a heterogenous cell population, *Br. J. Haematol.* 104 (1999) 530–537.
- [19] S. Mercier, H. Gahery-Segard, M. Monteil, R. Lengagne, J.G. Guillet, M. Eloit, C. Denesvre, Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product, *J. Virol.* 76 (2002) 2899–2911.
- [20] G. Miller, S. Lahrs, V.G. Pillarisetty, A.B. Shah, R.P. DeMatteo, Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection, *Cancer Res.* 62 (2002) 5260–5266.
- [21] I. Mellman, R.M. Steinman, Dendritic cells: specialized and regulated antigen processing machines, *Cell* 106 (2001) 255–258.
- [22] F. Sallusto, M. Cella, C. Danieli, A. Lanzavecchia, Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products, *J. Exp. Med.* 182 (1995) 389–400.
- [23] A. Camporeale, A. Boni, G. Iezzi, E. Degl'Innocenti, M. Grioni, G. Mondino, M. Bellone, Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes, *Cancer Res.* 63 (2003) 3688–3694.
- [24] A. Langenkamp, M. Messi, A. Lanzavecchia, F. Sallusto, Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells, *Nat. Immunol.* 1 (2000) 311–316.
- [25] L. Alexopoulou, A.C. Holt, R. Medzhitov, R.A. Flavell, Recognition of double-stranded RNA and activation of NF- $\kappa$ B by Toll-like receptor 3, *Nature* 413 (2001) 732–738.
- [26] M. Yoneyama, M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. Taira, S. Akira, T. Fujita, The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses, *Nat. Immunol.* 5 (2004) 730–737.
- [27] N. Sadeghi, M.J. Black, M.P. Hier, G. Shenouda, S.E. Karp, Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma, *Arch. Otolaryngol. Head Neck Surg.* 123 (1997) 25–30.
- [28] S.A. Rosenberg, Shedding light on immunotherapy for cancer, *N. Engl. J. Med.* 350 (2004) 1461–1463.

# Neurospheres From Human Adipose Tissue Transplanted Into Cultured Mouse Embryos can Contribute to Craniofacial Morphogenesis: A Preliminary Report

Takashi Nagase, MD, PhD,\* Daisuke Matsumoto, MD,<sup>†</sup> Miki Nagase, MD, PhD,<sup>‡</sup> Kotaro Yoshimura, MD, PhD,<sup>†</sup> Tomokuni Shigeura, MS,<sup>†</sup> Makoto Inoue, PhD,<sup>§</sup> Mamoru Hasegawa, PhD,<sup>§</sup> Masaaki Yamagishi, MD, PhD,\* Masafumi Machida, MD, PhD\*

Tokyo, Japan

**Adipose-derived stromal cells (ASCs) are one of the most promising stem cell populations that differentiate into the mesodermal as well as neural lineages in vitro. In this study, we examined the neural differentiating potential of human ASCs by a neurosphere culture method. Neurospheres derived from human ASCs expressed *Nestin* and *Musashi-1* genes, which are marker genes for neural stem cells. When these cells were labeled with *green fluorescent protein* gene transfection by Sendai virus vector and transplanted into the head region of mouse embryos using a whole embryo culture system, these cells were incorporated into the craniofacial development. Some transplanted cells appeared to migrate along the second branchial arches, implicating some similarity to the cranial neural crest cells. Although preliminary, our results support an idea that ASC-derived neurospheres have properties of neural progenitors in vitro and in vivo.**

---

From the \*Clinical Research Center, National Hospital Organization Murayama Medical Center, Tokyo, Japan; <sup>†</sup>Department of Plastic and Reconstructive Surgery, <sup>‡</sup>Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan; and <sup>§</sup>DNAVEC Corporation, Tsukuba, Ibaraki, Japan.

Address correspondence and reprint requests to Dr. Takashi Nagase, Head, Division of Advanced Medical Research, Clinical Research Center, National Hospital Organization Murayama Medical Center, 2-37-1 Gakuen, Musashimurayama-City, Tokyo 208-0011, Japan; E-mail: tnagase@fb3.so-net.ne.jp

The first two authors contributed equally to this work.

---

**Key Words:** Adipose-derived stromal cells, neurosphere, neural stem cells, embryo, stem cells

**A**dipose-derived stromal cells (ASCs) were originally reported as a subtype of the mesenchymal stem cells (MSCs) isolated from liposuction aspirates differentiating into the mesodermal tissues such as bone, cartilage, and adipose tissue.<sup>1</sup> Characterization of ASCs has recently been studied world wide by many groups, including ours.<sup>2-4</sup> ASCs are now regarded as one of the most promising adult stem cells for regenerative medicine because they can be harvested safely by liposuction, and a good yield can be anticipated.

Advances in stem cell research have resulted in a novel concept of cellular plasticity of differentiation beyond the boundary of germ layers. MSCs and ASCs can differentiate into neuronal (and thus ectodermal) derivatives, although these cells are primarily mesodermal.<sup>5,6</sup> Recent reports further indicate that stem cells with neural characteristics can be isolated from the mesodermal tissues such as the dermis and the heart.<sup>7-9</sup> In these cases, the cells were harvested by a neurosphere method, which was originally developed as a culture method of isolating spheres of neural stem cells from the embryonic and adult brain.<sup>10-12</sup> However, it is to be elucidated whether this method is also applicable for obtaining neural stem cells from the adipose tissue or ASCs.

In this study, the neurospheres expressing neural stem cell marker genes were obtained from human ASCs. We also transplanted these cells into mouse embryos cultured in vitro to examine whether these cells behave similar to neuronal cells in vivo.




Fig 1 Neurosphere formation of adipose-derived stromal cells cultured in neurosphere medium for 5 days (A), 6 days (B), and 7 days (C) (magnification  $\times 200$ ).

**MATERIALS AND METHODS**

**Isolation of Human ASCs and Neurosphere Cell Culture**

ASCs were isolated from the human liposuction aspirates as reported previously.<sup>3</sup> The suctioned fat was digested with 0.075% collagenase in phosphate-buffered saline (PBS) for 30 minutes on a shaker at 37°C. Mature adipocytes and connective tissues were eliminated by centrifugation. Blood cells were also eliminated by treating with erythrocyte lysis buffer, and resultant ASC pellets were obtained. Alternatively, ASCs could be isolated from the fluid portions of liposuction aspirates by treating with erythrocyte lysis buffer and density gradient centrifugation with Ficoll (GE Healthcare Bio-sciences, Piscataway, NJ).

Neurosphere culture was performed as described previously with slight modification.<sup>12</sup> Freshly isolated ASCs were plated at a density of  $2 \times 10^7$  cells in 10 cm uncoated dishes and cultured in the neurosphere culture medium at 37°C in an atmosphere of 5% CO<sub>2</sub> in humid air. The neurosphere medium was a Dulbecco's Modified Eagle's Medium/F12 (1:1)-based medium supplemented with human recombinant epidermal growth factor (EGF, 20 ng/mL, PeproTech, Rocky Hill,

NJ), human recombinant basic fibroblast growth factor (FGF, 20 ng/mL, Kaken Pharmaceutical, Tokyo, Japan), 2% B27 supplement (Gibco, Carlsbad, CA), 100 U/mL penicillin, and 100 µg/mL streptomycin. Half of the medium was replaced with a fresh medium on the fourth to fifth day, and the passaging was performed on the eighth day.

**Quantitative Real-Time Reverse-Transcriptase Polymerase Chain Reaction**

Total mRNA was extracted using RNeasy-mini kit (Qiagen, Hilden, Germany) from the neurosphere cells derived from passage one ASCs, which were precultured in the normal medium containing M199 medium and 10% fetal bovine serum (FBS). The preculturing was necessary for reducing the contamination of blood cells. Control mRNA was also extracted from the passage one undifferentiated ASCs cultured in M199 plus 10% FBS.

Expressions of undifferentiated neural stem cell marker genes *Nestin* and *Musashi-1*<sup>13</sup> and adipogenic differentiation marker *Leptin* were analyzed by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) using an ABI PRISM 7700




Fig 2 Quantitative real-time reverse-transcription polymerase chain reaction analysis of gene expressions of neural stem cell marker *Nestin* (A), *Musashi-1* (B), and adipogenic differentiation marker *Leptin* (C). Control = undifferentiated adipose-derived stromal cells; Sphere = neurospheres. Assays were performed in triplicate, and standard errors are indicated by error bars.

(Applied Biosystems, Foster City, CA), as reported previously. Gene expression of the target sequence was normalized to that of the housekeeping gene  $\beta$ -actin. Transcript level in the control (undifferentiated ASC) group was arbitrarily expressed as 1. TaqMan chemistry and assay by design primers and probe sets were used for human *Nestin*, *Musashi-1*, *Leptin*, and  $\beta$ -actin. All the primers and probe sets were purchased from Applied Biosystems.

#### Mouse Whole Embryo Culture and Transplantation of Neurosphere-Like Cells

Neurospheres derived from human ASCs were transfected with *green fluorescent protein (GFP)* gene using the Sendai virus vector (DNAVEC Corp. Tsukuba, Japan), as reported previously.<sup>14,15</sup> The original vector SeV/ $\Delta$ F lacks the F gene encoding fusion protein necessary for penetration of ribonucleoprotein complex into infected cells, and is thus nontransmissible and nonpathogenic.<sup>14</sup> The modified SeV/ $\Delta$ F vector has additional mutations to reduce its cytotoxicity,<sup>15</sup> and we used the modified vector in the present study. Neurospheres were incubated for 1 hour in the medium with the modified SeV/ $\Delta$ F carrying the *GFP* gene at a multiplicity of infection of 250 and rinsed with PBS.


Mouse whole embryo culture was performed as reported previously.<sup>16–19</sup> Nine mouse embryos at embryonic day (E) 8 were dissected out without damaging yolk sacs, and the GFP-transfected neurosphere cells were transplanted using micropipettes into the head region of the embryos. The embryos were cultured for approximately 40 hours, and presence or absence of the GFP-positive transplanted cells was investigated under a fluorescent dissecting microscope. All experimental procedures were performed at the University of Tokyo under approval of the ethical committee.

#### RESULTS

**W**e first cultured human ASCs in the neurosphere culture medium containing EGF and basic FGF without serum. On the third day of culture of freshly prepared ASCs, the floating ASCs started to form small masses (data not shown). The neurosphere-like cellular aggregates were clearly observed on the fifth day (Fig 1A). The number and the size of the spheres became increasingly larger within the next 2 days (Fig 1, B and C). The passaging was performed on the eighth day when the spheres were dissociated and resuspended in the new medium.

The spheroids were newly formed after culturing again for several days (data not shown), suggesting self renewal of the neurosphere cells.

To characterize the neurosphere cells, we next examined expressions of neural stem cell marker *Nestin* and *Musashi-1* genes and adipocyte marker *Leptin* by quantitative real-time RT-PCR. Expressions of *Nestin* and *Musashi-1* genes were remarkably up-regulated in the neurosphere cells compared with the control ASCs without culturing in the neurosphere medium (Fig 2, A and B), suggesting characteristics of neural progenitor. Conversely, *Leptin* expression



**Fig 3** Neural crest-like migrations of green fluorescent protein (GFP)-transfected, adipose-derived stromal cell-derived neurospheres grafted into mouse embryo cultured in vitro. (A) Appearances of mouse embryos cultured for 40 hours from embryonic day 8. (B and C) Fluorescent views of embryos. GFP-positive neurosphere cells were arranged in a row (arrows), suggesting their migration along second branchial arch. Bars = 500  $\mu$ m.



was dramatically reduced in the neurospheres (Fig 2C), indicating loss of adipogenic potential.

To investigate functions of the neurosphere cells *in vivo*, we labeled these cells by the modified Sendai virus vector carrying the *GFP* gene and transplanted them into the head region of the E8 mouse embryos. After the embryos were cultured for approximately 40 hours *in vitro*, the transplanted GFP-positive cells were clearly observed and appeared viable in only two embryos of the nine cultured embryos. The GFP-positive cells were incorporated into the craniofacial region as well as the heart and the trunk in these two embryos (Fig 3). Notably, the transplanted cells were arranged in a row along the second branchial arch (arrows in Fig 3, B and C) in a quite similar pattern to the neural crest cells migrating within the second branchial arch. Although not confirmatory, this result suggests a intriguing possibility that neurosphere cells derived from ASCs have neural crest-like properties.

## DISCUSSION

ASCs are probably one of the most well-known stem cells among plastic surgeons. ASCs were originally reported by Zuk et al<sup>1</sup> from the clinical samples of liposuction aspirates. According to their broad spectrum of differentiation potential, ASCs have been used in a number of preclinical animal studies of *in vivo* regeneration of a various tissues such as bone,<sup>20,21</sup> cartilage,<sup>22</sup> vessels,<sup>4,23,24</sup> soft tissue,<sup>4</sup> bone marrow,<sup>25</sup> and so on. Even a clinical case was reported, in which a calvarial defect was repaired by ASCs combined with scaffold.<sup>26</sup> Several groups reported neural differentiation of ASCs *in vitro*,<sup>5,6,27</sup> and Kang et al<sup>28</sup> reported functional recovery of the rat model with cerebral infarction after ASC transplantation *in vivo*.

The neurosphere method was originally reported by Reynolds et al<sup>10,11</sup> and is one of the most frequently used methods for isolating neural stem cells from the embryo or from the adult central nervous systems. However, this method has not yet been applied for obtaining neural stem cells from adipose tissue or the ASC population. In this preliminary study, we obtained neurospheres from the ASCs in human liposuction aspirates. Proliferation of these cells was quite rapid, possibly faster than other neurospheres from various tissue origins such as the dermis and the heart,<sup>7-9</sup> suggesting advantages of ASCs as a origin of neuronal progenitors for regenerative medicine. These neurosphere cells expressed *Nestin* and *Musashi-1*, marker genes for neural stem cells, probably reflecting their

tendency of differentiating into neuronal progenitors. This view is further supported by inhibition of their expression of *Leptin*, a marker for adipogenic differentiation and maturation.

Do the ASC-derived neurosphere cells behave as neuronal progenitors *in vivo*? Our attempt of grafting these cells into the cultured mouse embryo revealed that some of the cells migrate along the second branchial arch and contribute to craniofacial morphogenesis. Their migratory pattern is quite similar to that of cranial neural crest cells, as we reported previously.<sup>16</sup> The neural crest cells are an embryonic cellular population characterized by extensive migration and a unique repertoire of differentiation.<sup>29</sup> The neural crest cells are often regarded as stem or progenitor cells for peripheral neurons and Schwann cells, and the craniofacial skeletal mesenchyme is also neural-crest derived.<sup>17,19,29,30</sup> Recent studies indicate that the neural crest stem cells can be harvested from the seemingly "mesodermal" tissues of adult animals, such as the dermis,<sup>7</sup> the hair follicular dermal papilla,<sup>8</sup> or the heart,<sup>9</sup> by means of the neurosphere method, implicating that it is also the case in the adipose tissue. Because our data are preliminary and we have a small sample size, further studies such as those with detailed expression analysis of neural/neural crest marker genes and large-scale *in vivo* grafting are necessary to confirm this interesting idea.

## REFERENCES

1. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng* 2001;7:211-228
2. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell* 2002;13:4279-4295
3. Yoshimura K, Shigeura T, Matsumoto D, et al. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. *J Cell Physiol* 2006;208:64-76
4. Matsumoto D, Sato K, Gonda K, et al. Cell-assisted lipotransfer (CAL): supportive use of human adipose-derived cells for soft tissue augmentation with lipoinjection. *Tissue Eng*. In Press.
5. Ashjian PH, Elbarbary AS, Edmonds B, et al. *In vitro* differentiation of human processed lipoaspirate cells into early neural progenitors. *Plast Reconstr Surg* 2003;111:1922-1931
6. Kokai LE, Rubin JP, Marra KG. The potential of adipose-derived adult stem cells as a source of neuronal progenitor cells. *Plast Reconstr Surg* 2005;116:1453-1460
7. Toma JG, Akhavan M, Fernandes KJ, et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. *Nat Cell Biol* 2001;3:778-784
8. Fernandes KJ, McKenzie IA, Mill P, et al. A dermal niche for multipotent adult skin-derived precursor cells. *Nat Cell Biol* 2004;6:1082-1093
9. Tomita Y, Matsumura K, Wakamatsu Y, et al. Cardiac neural crest cells contribute to the dormant multipotent stem cell in the mammalian heart. *J Cell Biol* 2005;170:1135-1146
10. Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive

- striatal embryonic progenitor cell produces neurons and astrocytes. *J Neurosci* 1992;12:4565–4574
11. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. *Science* 1992;255:1707–1710
  12. Kanemura Y, Mori H, Kobayashi S, et al. Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using indirect measurements of viable cells based on cellular metabolic activity. *J Neurosci Res* 2002;69:869–879
  13. Kaneko Y, Sakakibara S, Imai T, et al. Musashi-1: an evolutionally conserved marker for CNS progenitor cells including neural stem cells. *Dev Neurosci* 2000;22:139–153
  14. Li HO, Zhu YF, Asakawa M, et al. A cytoplasmic RNA vector derived from nontransmissible sendai virus with efficient gene transfer and expression. *J Virol* 2000;74:6564–6569
  15. Inoue M, Tokusumi Y, Ban H, et al. Nontransmissible virus-like particle formation by F-deficient sendai virus is temperature sensitive and reduced by mutations in M and HN proteins. *J Virol* 2003;77:3238–3246
  16. Nagase T, Sanai Y, Nakamura S, et al. Roles of HNK-1 carbohydrate epitope and its synthetic glucuronyltransferase genes on migration of rat neural crest cells. *J Anat* 2003;203:77–88
  17. Nagase T, Nagase M, Osumi N, et al. Craniofacial anomalies of the cultured mouse embryo induced by inhibition of sonic hedgehog signaling: an animal model of holoprosencephaly. *J Craniofac Surg* 2005;16:80–88
  18. Nagase T, Nagase M, Yoshimura K, et al. Angiogenesis within the developing mouse neural tube is dependent on sonic hedgehog signaling: possible roles of motor neurons. *Genes Cells* 2005;10:595–604
  19. Yamada Y, Nagase T, Nagase M, et al. Gene expression changes of sonic hedgehog signaling cascade in a mouse model of fetal alcohol syndrome. *J Craniofac Surg* 2005;16:1055–1061
  20. Cowan CM, Shi YY, Aalami OO, et al. Adipose-derived adult stromal cells heal critical-size mouse calvarial defects. *Nat Biotechnol* 2004;22:560–567
  21. Dragoo JL, Lieberman JR, Lee RS, et al. Tissue-engineered bone from bmp-2-transduced stem cells derived from human fat. *Plast Reconstr Surg* 2005;115:1665–1673
  22. Dragoo JL, Samimi B, Zhu M, et al. Tissue-engineered cartilage and bone using stem cells from human infrapatellar fat pads. *J Bone Joint Surg Br* 2003;85:740–747
  23. Planat-Benard V, Silvestre JS, Cousin B, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. *Circulation* 2004;109:656–663
  24. Miranville A, Heeschen C, Sengenès C, et al. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. *Circulation* 2004;110:349–355
  25. Cousin B, Andre M, Arnaud E, et al. Reconstitution of lethally irradiated mice by cells isolated from adipose tissue. *Biochem Biophys Res Commun* 2003;301:1016–1022
  26. Lendeckel S, Jodicke A, Christophis P, et al. Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report. *J Craniomaxillofac Surg* 2004;32:370–373
  27. Fujimura J, Ogawa R, Mizuno H, et al. Neural differentiation of adipose-derived stem cells isolated from GFP transgenic mice. *Biochem Biophys Res Commun* 2005;333:116–121
  28. Kang SK, Lee DH, Bae YC, et al. Improvement of neurological deficits by intracerebral transplantation of human adipose tissue-derived stromal cells after cerebral ischemia in rats. *Exp Neurol* 2003;183:355–366
  29. Le Douarin N, Kalcheim C. *The Neural Crest*, ed 2. Cambridge: Cambridge University Press, 1999
  30. Nagase T, Nakamura S, Harii K, et al. Ectopically localized HNK-1 epitope perturbs migration of the midbrain neural crest cells in pax6 mutant rat. *Dev Growth Differ* 2001;43:683–692